星昊医药
(920017)
| 流通市值：19.83亿 | | | 总市值：20.05亿 |
| 流通股本：1.23亿 | | | 总股本：1.25亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 499,078,468.47 | 314,456,566.52 | 158,348,371.9 | 650,139,997.82 |
| 营业收入 | 499,078,468.47 | 314,456,566.52 | 158,348,371.9 | 650,139,997.82 |
| 二、营业总成本 | 396,517,488.5 | 268,138,160.67 | 130,347,236.65 | 542,987,849.51 |
| 营业成本 | 144,941,568.99 | 93,435,772.27 | 43,813,840.88 | 194,932,802.94 |
| 税金及附加 | 6,735,351.3 | 4,696,425.22 | 1,763,236.98 | 10,092,895.94 |
| 销售费用 | 173,862,555.79 | 116,035,516.63 | 54,985,922.13 | 223,924,756.12 |
| 管理费用 | 28,519,017.24 | 19,245,562.6 | 10,954,380.34 | 47,678,185.11 |
| 研发费用 | 45,940,815.62 | 36,980,761.08 | 19,942,828.69 | 75,475,769.96 |
| 财务费用 | -3,481,820.44 | -2,255,877.13 | -1,112,972.37 | -9,116,560.56 |
| 其中:利息费用 | 178,861.1 | 118,805.55 | 58,750 | 259,388.88 |
| 其中:利息收入 | 4,819,624.46 | 3,253,136.25 | 1,725,787.52 | 8,519,477.96 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,451,021.51 | 3,481,390.42 | 1,613,986.31 | 3,538,306.82 |
| 加:投资收益 | 5,278,627.86 | 1,819,917.16 | 869,620.99 | 3,802,693.03 |
| 资产处置收益 | 2,103.32 | - | - | -36.47 |
| 资产减值损失(新) | -3,685,818.36 | -2,728,950.96 | -178,002.33 | -6,368,590.38 |
| 信用减值损失(新) | 2,046,542.78 | 572,730.29 | 164,100.13 | -11,937,839.42 |
| 其他收益 | 17,375,875.87 | 10,398,189.24 | 5,690,921.99 | 21,234,860.52 |
| 四、营业利润 | 126,029,332.95 | 59,861,682 | 36,161,762.34 | 117,421,542.41 |
| 加:营业外收入 | 416,526.78 | 309,358.95 | 0 | 1,008,397 |
| 减:营业外支出 | 2,352,914.9 | 2,041,945.25 | 50,000 | 492,746.5 |
| 五、利润总额 | 124,092,944.83 | 58,129,095.7 | 36,111,762.34 | 117,937,192.91 |
| 减:所得税费用 | 13,842,453.03 | 4,889,021.61 | 4,322,820.27 | 14,892,393.8 |
| 六、净利润 | 110,250,491.8 | 53,240,074.09 | 31,788,942.07 | 103,044,799.11 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 110,250,491.8 | 53,240,074.09 | 31,788,942.07 | 103,044,799.11 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 110,250,491.8 | 53,240,074.09 | 31,788,942.07 | 103,044,799.11 |
| 扣除非经常损益后的净利润 | 101,953,128.15 | 49,386,925.03 | 28,878,516.25 | 93,832,768.2 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.88 | 0.43 | 0.25 | 0.84 |
| (二)稀释每股收益 | 0.88 | 0.43 | 0.25 | 0.84 |
| 八、其他综合收益 | -617,625.04 | -723,739.64 | -1,172.31 | -3,828,310.05 |
| 归属于母公司股东的其他综合收益 | -617,625.04 | -723,739.64 | -1,172.31 | -3,828,310.05 |
| 九、综合收益总额 | 109,632,866.76 | 52,516,334.45 | 31,787,769.76 | 99,216,489.06 |
| 归属于母公司股东的综合收益总额 | 109,632,866.76 | 52,516,334.45 | 31,787,769.76 | 99,216,489.06 |
| 归属于少数股东的综合收益总额 | - | 0 | - | 0 |
| 公告日期 | 2026-10-28 | 2026-08-10 | 2026-04-29 | 2026-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |